Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)

Eno Inyang, PharmD, BCPS, Nikhil C. Munshi, MD, Anil Aktas-Samur, PhD, Houry Leblebjian, PharmD, BCOP

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-136342

Published: 2020

Journal Articles

Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma

Shawn O. Streeter, PharmD, Omar Nadeem, MD, Paul G. Richardson, MD, Jacob P. Laubach, MD, Clifton C. Mo, MD, Kimberly Noonan, RN, NP, AOCN, Mary McKenney, NP, Tina Flaherty, ANP-BC, AOCN, Virginia Dalton, MS, APRN, Anil Aktas-Samur, PhD, Houry Leblebjian, PharmD, BCOP

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-143385

Published: 2020

Journal Articles

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142514

Published: 2020

Journal Articles

Activation of the ERK Pathway Drives Acquired Resistance to Venetoclax in MM Cell Models

Chandraditya Chakraborty, PhD, Yan Xu, MD, Yao Yao, Eugenio Morelli, MD, Anil Aktas-Samur, PhD, Mehmet Kemal Samur, PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD, Kenneth Anderson, MD, Chandraditya Chakraborty, PhD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-142655

Published: 2020

Journal Articles

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

Mehmet K. Samur, PhD, Marco Roncador, MD MSc, Anil Aktas-Samur, PhD, Mariateresa Fulciniti, PhD, Abdul Hamid Bazarbachi, MD, Raphael Szalat, Masood A. Shammas, PhD, Adam S Sperling, MD PhD, Paul G. Richardson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Anjan Thakurta, Aurore Perrot, Jill Corre, PharmD, PhD, Philippe Moreau, MD, Kenneth Anderson, MD, Giovanni Parmigiani, PhD, Herve Avet-Loiseau, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-139014

Published: 2020

Journal Articles

High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

Anil Aktas-Samur, PhD, Mariateresa Fulciniti, PhD, Sanika Derebail, MS, Raphael Szalat, Giovanni Parmigiani, PhD, Jill Corre, PharmD, PhD, Herve Avet-Loiseau, Mehmet K. Samur, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-139066

Published: 2020

Journal Articles

Exploring POU2AF1 ( BOB-1 ) D ependency and Transcription Addiction in Multiple Myeloma

Zuzana Chyra, PhD, Mehmet Kemal Samur, PhD, Anil Aktas-Samur, PhD, Yan Xu, MD, Eugenio Morelli, MD, Sophia Adamia, PhD, Woojun D Park, Lin Charles, PhD, Masood A. Shammas, PhD, Roman Hajek, MD PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 49.

https://doi.org/10.1182/blood-2020-142587

Published: 2020

Journal Articles

Atpase Family AAA Domain-Containing Protein 2 (ATAD2) As a Novel Target in Multiple Myeloma

Lakshmi B. Potluri, MBBS, Srikanth Talluri, PhD, Leutz Buon, Mehmet K. Samur, PhD, Anil Aktas-Samur, PhD, Jialan Shi, MDPhD, Chandraditya Chakraborty, PhD, Subodh Kumar, PhD, Rao Prabhala, Masood A. Shammas, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 50.

https://doi.org/10.1182/blood-2020-140466

Published: 2020

Journal Articles

Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature

Abdul Hamid Bazarbachi, MD, Herve Avet-Loiseau, Zachary R Hunter, PhD, Raphael Szalat, Anil Aktas-Samur, PhD, Masood A. Shammas, PhD, Jill Corre, PharmD, PhD, Mariateresa Fulciniti, PhD, Kenneth Anderson, MD, Giovanni Parmigiani, PhD, Steven Treon, Mohamad Mohty, MD PhD, Mehmet K. Samur, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-138951

Published: 2020

Journal Articles

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma

Mehmet K. Samur, PhD, Mariateresa Fulciniti, PhD, Anil Aktas-Samur, PhD, Abdul Hamid Bazarbachi, MD, Yu-Tzu Tai, PhD, Timothy B. Campbell, MD PhD, Fabio Petrocca, MD, Kristen Hege, MD, Shari Kaiser, PhD, Kenneth Anderson, MD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-139040

Published: 2020

Journal Articles

Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy: Real-World Examination of the Impede Study

Grace Hwang, PharmD, Audrea Szabatura, PharmD, Houry Leblebjian, PharmD, BCOP, Anil Aktas-Samur, PhD, Jacob P. Laubach, MD, Aric D. Parnes, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-140175

Published: 2020

Journal Articles

The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche

Giada Bianchi, MD, Peter G. Czarnecki, MD, Matthew Ho, PhD, Aldo M. Roccaro, MD PhD, Antonio Sacco, RN, Yawara Kawano, MD PhD, Anil Aktas Samur, PhD, Annamaria Gulla, MD, Tianzeng Chen, Kenneth Wen, Xinchen Wu, Yu-Tzu Tai, PhD, Gulden Camci-Unal, PhD, Irene M. Ghobrial, MD, Ruben D. Carrasco, MD PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 507.

https://doi.org/10.1182/blood-2019-128778

Published: 2019

Journal Articles

Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple Myeloma

Eugenio Morelli, MD, Mariateresa Fulciniti, PhD, Mehmet Kemal Samur, PhD, Caroline Ribeiro, PhD, Leon Wert-Lamas, PhD, Annamaria Gulla, MD, Anil Aktas Samur, PhD, Cinzia Federico, PhD, Francesca Scionti, PhD, Yao Yao, PhD, Nicola Amodio, PhD, Giada Bianchi, MD, Yu-Tzu Tai, PhD, Pierfrancesco Tassone, MD, Kenneth C. Anderson, MD, Carl D. Novina, MD PhD, Massimo Loda, MD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 317.

https://doi.org/10.1182/blood-2019-130730

Published: 2019

Journal Articles

Genome Wide Transcriptomic Analysis Identifies Dysregulated Splicing Factor Profile with Molecular and Functional Role in Multiple Myeloma

Anil Aktas Samur, PhD, Mehmet Kemal Samur, PhD, Michael A Lopez, Sanika Derebail, Kenneth C. Anderson, MD, Herve Avet-Loiseau, MD PhD, Giovanni Parmigiani, PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 361.

https://doi.org/10.1182/blood-2019-129114

Published: 2019

Journal Articles

Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma

Tessa Han, Stephane Minvielle, PhD, Anil Aktas Samur, PhD, Mariateresa Fulciniti, PhD, Florence Magrangeas, PhD, Paul G. Richardson, MD, Philippe Moreau, MD, Michel Attal, MD PhD, Kenneth C. Anderson, MD, Hervé Avet-Loiseau, MD PhD, Giovanni Parmigiani, PhD, Mehmet Kemal Samur, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 4348.

https://doi.org/10.1182/blood-2019-130343

Published: 2019

Journal Articles

Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study

Anil Aktas Samur, PhD, Mariateresa Fulciniti, PhD, Raphael Szalat, Jill Corre, PharmD, PhD, Niccolo Bolli, MD PhD, Philippe Moreau, MD, Michel Attal, MD PhD, Kenneth C. Anderson, MD, Giovanni Parmigiani, PhD, Hervé Avet-Loiseau, MD PhD, Mehmet Kemal Samur, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 3089.

https://doi.org/10.1182/blood-2019-128570

Published: 2019

Journal Articles

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Mehmet Kemal Samur, PhD, Anil Aktas Samur, PhD, Tessa Han, Marco Roncador, MD MSc, Mariateresa Fulciniti, PhD, Raphael Szalat, Masood A. Shammas, PhD, Jill Corre, PharmD, PhD, Paul G. Richardson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Philippe Moreau, MD, Michel Attal, MD PhD, Anjan Thakurta, Kenneth C. Anderson, MD, Giovanni Parmigiani, PhD, Herve Avet-Loiseau, MD PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 3055.

https://doi.org/10.1182/blood-2019-128521

Published: 2019

Journal Articles

Dysregulation of Splicing in Multiple Myeloma: The Splicing Factor SRSF1 Supports MM Cell Proliferation Via Splicing Control

Mariateresa Fulciniti, PhD, Michael A Lopez, Anil Aktas Samur, PhD, Eugenio Morelli, MD, Hervé Avet-Loiseau, MD PhD, Mehmet Kemal Samur, PhD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 4500.

https://doi.org/10.1182/blood-2018-99-118845

Published: 2018

Journal Articles

Deciphering the Chronology of Copy Number Alterations in Multiple Myeloma (MM): What Comes First?

Anil Aktas Samur, PhD, Mehmet Kemal Samur, PhD, Stephane Minvielle, PhD, Florence Magrangeas, PhD, Masood A. Shammas, PhD, Mariateresa Fulciniti, PhD, Michel Attal, MD PhD, Philippe Moreau, Kenneth Anderson, MD, Giovanni Parmigiani, Hervé Avet-Loiseau, MD PhD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 3171.

https://doi.org/10.1182/blood-2018-99-120101

Published: 2018

Journal Articles

Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma

Mehmet Kemal Samur, PhD, Chandraditya Chakraborty, PhD, Raphael Szalat, MD, Anil Aktas Samur, PhD, Mariateresa Fulciniti, PhD, Michael A Lopez, Masood A. Shammas, PhD, Paul Richardson, Florence Magrangeas, PhD, Stephane Minvielle, PhD, Philippe Moreau, Michel Attal, Anjan Thakurta, PhD, Kenneth Anderson, MD, Giovanni Parmigiani, Hervé Avet-Loiseau, MDPhD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 190.

https://doi.org/10.1182/blood-2018-190

Published: 2018

NARROW

Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)

Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Activation of the ERK Pathway Drives Acquired Resistance to Venetoclax in MM Cell Models

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

Exploring POU2AF1 ( BOB-1 ) D ependency and Transcription Addiction in Multiple Myeloma

Atpase Family AAA Domain-Containing Protein 2 (ATAD2) As a Novel Target in Multiple Myeloma

Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma

Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy: Real-World Examination of the Impede Study

The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche

Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple Myeloma

Genome Wide Transcriptomic Analysis Identifies Dysregulated Splicing Factor Profile with Molecular and Functional Role in Multiple Myeloma

Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma

Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Dysregulation of Splicing in Multiple Myeloma: The Splicing Factor SRSF1 Supports MM Cell Proliferation Via Splicing Control

Deciphering the Chronology of Copy Number Alterations in Multiple Myeloma (MM): What Comes First?

Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only